The results indicate that a classical ketogenic diet may be more effective, and adult patients are likely to be less compliant with the KD than with an MAD
Clinical trial data paints a clear picture
CagriSema, a subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide, is administered once weekly in patients with type 2 diabetes and overweight Novo Nordisk In April 2022, phase 3 clinical trial to evaluate the efficacy and safety of tirzepatide in adults with obesity or overweight and at least one comorbidity apart from diabetes, delivered up to 22.5% weight loss Eli Lilly and Company's In January 2022, the has cleared Altimmune, Inc.s Investigational New Drug (IND) application for the Phase 2 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist under development, indicated for the treatment of obesity and non-alcoholic steatohepatitis (NASH)
That's a weight-loss drug demonstrating outcomes beyond the scale, in one of the highest-risk populations in medicine
FDA labeling and the American Diabetes Association recommend gradual dose titration to minimize gastrointestinal symptoms